Purpose-Evidence-Source Peptide Filter
Escalate only when the goal, evidence, source, and monitoring justify risk
- Difficulty
- Moderate
- Time to result
- ~days to results
- Steps
- 6
- Confidence
- 91%
This filter turns peptide enthusiasm into a sequence of risk questions. First define the exact problem: an injury, weight loss, sleep, fertility, or another measurable outcome. Next exhaust safer and better-supported fundamentals, because a compound should not substitute for sleep, training, or other relevant basics. Then separate strong human evidence from animal findings, mechanism, and anecdote. Compare the proposed peptide with alternatives whose dosing, purity, and adverse events are better characterized. If proceeding under medical care, sourcing matters because gray-market products can be contaminated or mislabelled. Establish relevant measurements before exposure, monitor during use, and stop when benefits fail to appear or a concerning signal emerges. The framework also treats missing adverse-event reports cautiously because weak reporting systems can make an immature intervention look safer than it is.
Origin
Extracted from The Tim Ferriss Show discussion of GLP drugs, growth-hormone secretagogues, BPC-157, pinealon, sourcing, and blood monitoring.
Core principles
- 01Start with the specific problem rather than enthusiasm for a compound
- 02Use fundamentals before poorly studied interventions
- 03Separate animal evidence, anecdotes, and human trials
- 04Unknown sourcing and weak adverse-event reporting increase uncertainty
- 05Measure outcomes and stop when harms outweigh benefits
How to run it
- 1
Define the job
State the specific condition or outcome the intervention should address. Reject ongoing use without a clear purpose.
Pro tip Use an outcome that can be measured rather than a vague desire for optimization.
Watch out A popular compound is not a diagnosis.
- 2
Clear the fundamentals
Apply the lower-risk behaviors that directly affect the target before escalating. For recovery or sleep, that includes correcting the obvious training, light, caffeine, and sleep issues first.
Pro tip A failed fundamental is a reason to fix the foundation, not proof that a peptide is needed.
- 3
Grade the evidence
Identify whether support comes from human trials, animal studies, mechanism, or anecdote. Check whether the studied outcome and dose actually match the proposed use.
Pro tip Treat impressive animal data as a research signal, not a human efficacy result.
Watch out Absence of reported harm is not proof of safety when reporting is poor.
- 4
Compare alternatives
Compare expected effect size, known risks, purity, cost, and monitoring requirements with better-characterized options. Prefer the path with the clearest risk-benefit profile.
Pro tip A familiar-sounding endogenous compound can still be poorly characterized at synthetic doses.
- 5
Control source and handling
If a clinician supports proceeding, use a legitimate prescription and the cleanest available source. Follow sterile injection practice when relevant.
Pro tip Cleaner sourcing reduces one uncertainty but does not establish efficacy.
Watch out Gray-market labels may not match vial contents and contamination is possible.
- 6
Measure and stop
Record baseline symptoms and relevant biomarkers, then repeat them during or after the trial. Stop when the intended benefit is absent or a concerning change appears.
Pro tip Use the shortest exposure capable of answering the defined question.
Watch out Do not rerun an experiment that already produced an unexplained adverse signal.
In the wild
Andrew Huberman described trying sermorelin briefly. He reported more slow-wave sleep, less REM sleep, and a rise in prostate-specific antigen; after he stopped, PSA returned to normal. He did not report meaningful fat loss or strength gain and said he would not repeat the experiment.
→ A measured adverse signal and weak benefit ended the trial.
A recreational trainee with persistent soreness first corrects sleep and workload, obtains a clinical assessment for injury, and reviews the absence of published human trials for BPC-157. Rather than buying a research-only vial, the trainee uses the diagnosis and evidence quality to decide with a clinician whether any intervention is justified.
→ The decision follows the problem and evidence instead of peptide popularity.
Common mistakes
Starting with the compound
Choosing a peptide before defining the problem encourages indefinite experimentation without a success criterion.
Equating endogenous with safe
A synthetic version delivered at much higher levels can have effects and risks unlike normal physiology.
Trusting a silent safety record
Poor adverse-event reporting can make a heavily used but weakly studied product appear safer than the evidence supports.
Is it for you?
Best for
It is best for adults discussing an experimental or prescription peptide with a qualified clinician.
Not ideal for
It is not ideal for self-prescribing gray-market compounds or bypassing medical care.
From the transcript
“There's not a single published human trial.”
“I've tried sermarelin very briefly, dramatically increased my slow wave deep sleep, nuked my REM sleep.”
“I came off it, PSA went back to normal.”
From the episode
#876: Dr. Andrew Huberman — Peptides, Performance, and Protocols
Andrew Huberman